Pharmacokinetics of guaifenesin following administration of multiple doses to exercised Thoroughbred horses.

The research article explores how the drug guaifenesin behaves in the bodies of exercised Thoroughbred horses following multiple oral doses, in a bid to determine an appropriate regulatory threshold and related withdrawal time for its use in performance horses.

Objective of the Study

• The study aimed to provide a comprehensive description of the pharmacokinetics of guaifenesin—an expectorant frequently employed to help clear mucus from the airways in performance horses—after its oral administration. It’s important to note that guaifenesin is a centrally acting skeletal muscle relaxant and therefore is a restricted substance, requiring a period of withdrawal before competition. Prior to this study, there were no documented evidence on single or multiple oral administrations of guaifenesin in horses to establish a regulatory threshold or suggest an appropriate withdrawal time.

Methodology

• The study was conducted on nine exercised Thoroughbred horses, each of which were given 2 grams of guaifenesin orally twice a day for five doses in total.
• Blood samples were collected from them immediately prior to drug administration and at different intervals after the administration of the drug. The serum guaifenesin concentrations were measured and pharmacokinetic parameters were calculated thereafter.

Findings

• The study found that guaifenesin was rapidly absorbed into the horses’ systems, with a Tmax (time to reach maximum concentration in the blood) of 15 minutes after oral administration.
• The Cmax (highest serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose) was measured at 681.3 ± 323.8 ng/mL following the first dose and 1080 ± 732.8 following the last dose.
• The serum elimination half-life (time required for the concentration of the drug in the body to be reduced by half) was found to be 2.62 ± 1.24 hours.
• Average serum guaifenesin concentrations remained above the limit of quantitation (LOQ—the lowest concentration of drug that can be quantitatively detected and reliably measured) of the assay (0.5 ng/mL) by 48 hours after the final dose in 3 of the 9 horses studied.

Significance

• The findings of the research are essential to establish appropriate regulatory recommendations for the use of guaifenesin in performance horses. An understanding of these pharmacokinetic parameters allows for the determination of a suitable withdrawal period that should precede any competition, thus ensuring that the drug does not influence the performance of the horses in a competition unfairly.